Abstract
Arab countries are projecting continuing growth in cancer incidence and mortality which require improvements in cancer policies and management. However, there are limited studies that investigate and compare the epidemiology of cancer incidence in Arab countries with only few studies addressing the age-specific rates across cancers. Based on the 2018 estimates from the Global Cancer Observatory, this study provides a comprehensive perspective of cancer burden in 2018 in Arab-speaking countries compared to the rest of the world. The age standardized rates for incidence and mortality for all cancers combined in Arab countries were lower than the global rates but the incidence rates of non-Hodgkin and Hodgkin lymphoma, bladder, breast, and liver cancers were higher. The top-most common cancers and incidence rates, even in age-specific groups, varied between sub-regions of Arab countries (the Levant, Arabian Gulf and Arab African sub-regions), and Iraq and Egypt, suggesting some common and unique environmental factors and possible ethnic or genetic heritages. Arab countries generally had higher mortality-to-incidence ratio than the world’s ratio. This study data is essential reference parameter to evaluate and monitor progress of national initiatives for surveillance programs and clinical management improvements tailored towards reducing cancer incidence and mortality in Arab countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Qatar Biomedical Research Institute (QBRI) - Hamad bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available in the Supplementary Data file included in the submission.
